RHYTHM PHARMACEUTICALS

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

07 Sep 2022 16:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Granted Marketing Authorization by European Commission for Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

06 Sep 2022 16:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Present at Investor Conferences in September

01 Sep 2022 08:00:01 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

08 Aug 2022 16:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Present at Canaccord Genuity 42nd Annual Growth Conference

03 Aug 2022 08:00:01 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Reports Second Quarter 2022 Financial Results and Business Update

02 Aug 2022 07:00:01 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Report Second Quarter 2022 Financial Results on Tuesday, August 2, 2022

28 Jul 2022 08:00:02 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Receives Positive CHMP Opinion for ▼¹ IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Bardet-Biedl Syndrome

22 Jul 2022 08:39:33 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Early Access Authorization for Setmelanotide for Use in Patients with Bardet-Biedl Syndrome in France

20 Jul 2022 08:00:02 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Early Access Authorization for Setmelanotide for Use in Patients with Bardet-Biedl Syndrome in France

20 Jul 2022 08:00:01 By Nasdaq GlobeNewswire

NICE Recommends Rhythm’s ▼IMCIVREE® (setmelanotide) for Treating Obesity and Controlling Hunger Caused by POMC or LEPR Deficiency

18 Jul 2022 06:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Positive Interim Results from Phase 2 Clinical Trial Evaluating Setmelanotide in Hypothalamic Obesity

12 Jul 2022 07:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

08 Jul 2022 09:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Launches IMCIVREE® (setmelanotide) in Germany for the Treatment of Obesity and Control of Hunger Associated with POMC or LEPR Deficiency

22 Jun 2022 08:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces that European Commission Authorized Variation for IMCIVREE® (setmelanotide) to Allow for Dosing in Patients with POMC or LEPR deficiency with Renal Impairment

22 Jun 2022 08:00:01 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Enters into a Non-dilutive Revenue Interest Financing Agreement with HealthCare Royalty for up to $100 Million

16 Jun 2022 16:02:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Use in Patients with Bardet-Biedl Syndrome

16 Jun 2022 16:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Presents Initial Data from Long-term Extension Trial Evaluating Setmelanotide in Rare Genetic Diseases of Obesity at ENDO 2022

13 Jun 2022 08:00:02 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Presents New Data from Long-term Extension Trial Evaluating Setmelanotide in Bardet-Biedl Syndrome or POMC or LEPR Deficiency Obesity at ENDO 2022

13 Jun 2022 08:00:01 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

02 Jun 2022 16:01:00 By Nasdaq GlobeNewswire